BR9913932A - Uso de análogos de glp-1 no tratamento de derrame - Google Patents

Uso de análogos de glp-1 no tratamento de derrame

Info

Publication number
BR9913932A
BR9913932A BR9913932-4A BR9913932A BR9913932A BR 9913932 A BR9913932 A BR 9913932A BR 9913932 A BR9913932 A BR 9913932A BR 9913932 A BR9913932 A BR 9913932A
Authority
BR
Brazil
Prior art keywords
glp
stroke
analogs
treatment
administered
Prior art date
Application number
BR9913932-4A
Other languages
English (en)
Inventor
Suad Efendic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9913932A publication Critical patent/BR9913932A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Patente de Invenção: <B>"USO DE ANáLOGOS DE GLP-1 NO TRATAMENTO DE DERRAME"<D>. A presente invenção proporciona um método de redução da mortalidade e morbidade associadas com derrame. GLP-1, um análogo de GLP-1 ou derivado de GLP-1 são administrados em uma dose efetiva para normalizar a glicose no sangue.
BR9913932-4A 1998-09-24 1999-09-22 Uso de análogos de glp-1 no tratamento de derrame BR9913932A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10171998P 1998-09-24 1998-09-24
PCT/US1999/022026 WO2000016797A2 (en) 1998-09-24 1999-09-22 Use of glp-1 or analogs in treatment of stroke

Publications (1)

Publication Number Publication Date
BR9913932A true BR9913932A (pt) 2001-10-16

Family

ID=22286048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913932-4A BR9913932A (pt) 1998-09-24 1999-09-22 Uso de análogos de glp-1 no tratamento de derrame

Country Status (12)

Country Link
EP (1) EP1115421B1 (pt)
JP (1) JP2002526454A (pt)
CN (1) CN1163267C (pt)
AT (1) ATE433324T1 (pt)
AU (1) AU766375B2 (pt)
BR (1) BR9913932A (pt)
CA (1) CA2344056A1 (pt)
DE (1) DE69940975D1 (pt)
ES (1) ES2325777T3 (pt)
MY (1) MY155270A (pt)
TW (1) TWI260986B (pt)
WO (1) WO2000016797A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6284725B1 (en) † 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
AU6323001A (en) 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
MXPA04002996A (es) * 2001-10-01 2004-07-15 Lilly Co Eli Peptidicos de tipo glucagon glp1 y tratamiento de insuficiencia respiratoria.
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
DE602004026113D1 (de) 2003-12-18 2010-04-29 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
EA012442B1 (ru) 2005-05-13 2009-10-30 Эли Лилли Энд Компани Пегилированные соединения glp-1
NZ565535A (en) 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
WO2009153960A1 (ja) 2008-06-17 2009-12-23 大塚化学株式会社 糖鎖付加ｇｌｐ－１ペプチド
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
CA2778890A1 (en) 2009-10-30 2011-05-05 Otsuka Chemical Co., Ltd. Glycosylated form of antigenic glp-1 analogue
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
JP6039569B2 (ja) * 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
KR101925620B1 (ko) 2010-12-16 2018-12-05 노보 노르디스크 에이/에스 Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
US9266940B2 (en) 2011-04-12 2016-02-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
DK3257524T3 (da) 2015-02-11 2020-11-23 Gmax Biopharm Llc Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein
CN105254720B (zh) * 2015-11-18 2018-10-09 暨南大学 一种多受体激动剂po13及应用
WO2018113340A1 (zh) * 2016-12-20 2018-06-28 中国药科大学 多肽p11及其用途
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN117320755A (zh) * 2020-12-16 2023-12-29 香港中文大学 一种逆转衰老性脑功能衰退的方法
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途
WO2023246928A1 (zh) * 2022-06-23 2023-12-28 广州银诺医药集团股份有限公司 一种改进的glp-1受体激动剂的融合蛋白和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
PT944648E (pt) * 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CA2312190A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations

Also Published As

Publication number Publication date
CN1322137A (zh) 2001-11-14
CN1163267C (zh) 2004-08-25
ES2325777T3 (es) 2009-09-16
TWI260986B (en) 2006-09-01
EP1115421B1 (en) 2009-06-10
ATE433324T1 (de) 2009-06-15
CA2344056A1 (en) 2000-03-30
MY155270A (en) 2015-09-30
DE69940975D1 (de) 2009-07-23
JP2002526454A (ja) 2002-08-20
AU6398599A (en) 2000-04-10
EP1115421A2 (en) 2001-07-18
AU766375B2 (en) 2003-10-16
WO2000016797A3 (en) 2000-05-25
WO2000016797A2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
DK261490D0 (da) New pharmaceutical compound
PT998287E (pt) Utilizacao de levobupivacaina
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
ES2157107T3 (es) Uso de moxonidina para el tratamiento del dolor neuropatico.
MY124071A (en) Treatment of viral disease in swine
GR3032224T3 (en) Therapeutic agent for threatened abortion.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
DE60120159D1 (de) Hautpflegemittel
FR2818147B1 (fr) Nouvelle application therapeutique d&#39;un derive de la thienyclyclohexylamine
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
EP1566180A3 (en) Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
AR006382A1 (es) Procedimiento para el tratamiento del envejecimiento cutaneo y de lesiones atroficas mediante la administracion de una preparacion conteniendoacido hialuronico y/o hialuronatos.
AR016920A1 (es) FORMULACIoN DE 8A-AZALIDAS uTIL PARA EL TRATAMIENTO O PREVENCIoN DE UNA INFECCION ENTÉRICA O RESPIRATORIA BACTERIANA
UA19504A (uk) Засіб для лікуваhhя гhійhих запалеhь шкіри та підшкірhої клітковиhи
IT1261863B (it) Preparazioni farmaceutiche orali, a base di diltiazem, a cessione protratta e controllata, con le quali e&#39; possibile adottare una sola somministrazione giornaliera.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.